Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent (NYSE: A) will release fourth-quarter fiscal 2025 results after market close on Monday, Nov. 24, 2025. The company will host a listen-only conference call webcast at 1:30 p.m. PST the same day, with a recording available on Agilent's investor website for 90 days.
Agilent reported $6.51 billion revenue in fiscal 2024 and employs approximately 18,000 people. Webcast access is via the Events section of Agilent's Investor Relations site; investor and media contacts are provided for follow-up.
Agilent (NYSE: A) named Adam S. Elinoff as chief financial officer, effective Nov. 17, 2025. Elinoff joins from Amgen after 19 years, most recently serving as vice president of finance and treasurer, and previously managing a $6 billion P&L across 67 markets as regional CFO. Agilent reported $6.51 billion revenue for fiscal 2024. Rodney Gonsalves will return to his role as corporate controller and principal accounting officer.
The appointment emphasizes Elinoff’s experience in finance, strategy, M&A, and global transformations as Agilent executes its Ignite Operating System.
Agilent Technologies (NYSE: A) has launched its new Insight Series Alarm Resolution Systems for airport security screening, featuring the Insight300M and InsightBLS models. These advanced liquid explosive detection systems (LEDs) are designed to screen liquids, aerosols, and gels (LAGs) at airport checkpoints.
The systems boast the industry's lowest false alarm rate and rapid scan times, capable of identifying threats through complex barriers and multi-layered materials. A key feature is their future-proof design, allowing updates through software upgrades without hardware replacement. The launch builds on Agilent's 2017 acquisition of Cobalt Light Systems and will be showcased at the International Security Expo in London.
Agilent Technologies (NYSE: A) has launched the new Altura Ultra Inert HPLC Columns, designed specifically for biotherapeutics applications. The innovative columns demonstrate up to 2x sensitivity and 3x signal-to-noise ratio compared to competitors, while achieving up to 30x higher peak area when used with Agilent's 1290 Infinity III Bio LC.
The Altura line addresses critical needs in biopharma testing, particularly for peptide GLP-1 and oligonucleotide therapeutic development. Early testing shows a 30% increase in sensitivity and reduced peak tailing for acidic peptides and excipients analysis, offering superior chromatographic performance through faster conditioning, improved peak shape, and enhanced sensitivity.
Agilent Technologies (NYSE: A) has announced a nonexclusive collaboration with Lunit (KRX:328130.KQ) to develop AI-powered companion diagnostic solutions. The partnership combines Lunit's artificial intelligence expertise with Agilent's tissue-based diagnostic capabilities to enhance biomarker testing accuracy.
The collaboration will initially focus on developing AI-powered assays for research and clinical trials, integrating Lunit's AI algorithms with Agilent's state-of-the-art assays. The joint solutions aim to support pharmaceutical companies in companion diagnostic product development, potentially accelerating the development of biomarker-driven therapies and improving patient treatment precision.
Agilent Technologies (NYSE: A) has declared a quarterly dividend of 24.8 cents per share of common stock. The dividend will be paid on October 22, 2025, to shareholders of record as of September 30, 2025. Future dividend payments remain subject to board approval.
Agilent Technologies (NYSE: A) announced that President and CEO Padraig McDonnell will participate in a fireside chat at the Bank of America Global Healthcare Conference in London. The presentation is scheduled for September 25, 2025, from 9:50-10:30 AM BST. Investors can access both the live audio webcast and replay through Agilent's Investor Relations website.
Agilent Technologies (NYSE: A) has achieved the highest level of My Green Lab Certification—Green level—at its Refurbishment Centers in Delaware, USA, and Singapore. The centers scored 90% and 87% respectively in rigorous sustainability assessments across 12 critical categories.
The certification highlights Agilent's Certified Pre-Owned (CPO) program, which restores used instruments to factory-grade condition, supporting a circular lab economy through trade-in and buy-back options. Approximately 50% of refurbishment team members have become My Green Lab Ambassadors, demonstrating the company's commitment to sustainability.
Agilent Technologies (NYSE: A) announced its participation as a premium sponsor at the European Congress of Pathology (ECP) 2025 in Vienna, Austria, from September 6-10, 2025. The company will showcase the European launch of its expanded Dako Omnis Family of instruments, including the Dako Omnis 110, 165, and 165 Duo models.
The event will feature live demonstrations, expert sessions, and educational symposia focusing on diagnostic excellence and workflow optimization. Visitors can explore Agilent's Digital Pathology solutions and participate in PD-L1 CPS scoring sessions at booth #18.
Agilent Technologies (NYSE: A) has achieved a significant regulatory milestone as its MMR IHC Panel pharmDx (Dako Omnis) received European IVDR certification as a class C companion diagnostic test for colorectal cancer. The panel is specifically designed to identify mismatch repair (MMR) deficient CRC patients who may be eligible for treatment with OPDIVO® in combination with YERVOY®.
The diagnostic panel is uniquely positioned as the only companion diagnostic IHC panel IVDR approved for this specific treatment combination in colorectal cancer patients. The test works by detecting the loss of function in four key MMR proteins (MLH1, PMS2, MSH2, and MSH6) in tissue samples, helping identify patients who may respond better to immunotherapy.